Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: The creation of the health consumer: challenges on health sector regulation after managed care era | Iriart et al. Globalization and Health 2011 7 2 http content 7 1 2 H2 globalization 7 AND HEALTH RESEARCH Open Access The creation of the health consumer challenges on health sector regulation after managed care era Celia Iriart1 Tulio Franco2 Emerson E Merhy3 Abstract Background We utilized our previous studies analyzing the reforms affecting the health sector developed in the 1990s by financial groups to frame the strategies implemented by the pharmaceutical industry to regain market positions and to understand the challenges that regulatory agencies are confronting. Methods We followed an analytical approach for analyzing the process generated by the disputes between the financial groups and the pharmaceutical corporations and the challenges created to governmental regulation. We analyzed primary and secondary sources using situational and discourse analyses. We introduced the concepts of biomedicalization and biopedagogy which allowed us to analyze how medicalization was radicalized. Results In the 1990s structural adjustment policies facilitated health reforms that allowed the entrance of multinational financial capital into publicly-financed and employer-based insurance. This model operated in contraposition to the interests of the medical industrial complex which since the middle of the 1990s had developed silent reforms to regain authority in defining the health-ill-care model. These silent reforms radicalized the medicalization. Some reforms took place through deregulatory processes such as allowing direct-to-consumer advertisements of prescription drugs in the United States. In other countries different strategies were facilitated by the lack of regulation of other media such as the internet. The pharmaceutical industry also has had a role in changing disease definitions rebranding others creating new ones and pressuring for approval of treatments to be paid by public employer and private plans. In recent years in Brazil .
